[HTML][HTML] EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to …
D Sentana-Lledo, E Academia, H Viray… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review
on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - PMC …
on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - PMC …
A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
Lung cancer is amongst the most pervasive malignancies having high mortality rates. It is
broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer …
broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer …
Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach
S Marks, J Naidoo - Lung Cancer, 2022 - Elsevier
The current standard-of-care for the treatment of advanced non-small cell lung cancer
(NSCLC) incorporates targeted therapies, immune-checkpoint inhibitors (ICI) and systemic …
(NSCLC) incorporates targeted therapies, immune-checkpoint inhibitors (ICI) and systemic …
Management of HER2 alterations in non-small cell lung cancer–The past, present, and future
HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …
distinct molecular alterations identified via next generation sequencing (NGS). Previously …
A pharmacological exploration of targeted drug therapy in non-small cell lung cancer
AP Jayan, KR Anandu, K Madhu, VN Saiprabha - Medical Oncology, 2022 - Springer
Lung cancer is the prime cause of cancer-related deaths globally, with a contribution of 85%
from non-small cell lung cancer. Before a few decades back, conventional chemotherapy …
from non-small cell lung cancer. Before a few decades back, conventional chemotherapy …
[HTML][HTML] Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions
J Yu, M Li, X Liu, S Wu, R Li, Y Jiang, J Zheng… - Biomedicine & …, 2024 - Elsevier
In recent decades, there has been a surge in the approval of monoclonal antibodies for
treating a wide range of hematological and solid malignancies. These antibodies exhibit …
treating a wide range of hematological and solid malignancies. These antibodies exhibit …
Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay
Recently, low human epidermal growth factor receptor 2 (HER2) protein expression has
been proposed as a predictive biomarker for response to the antibody-drug conjugate …
been proposed as a predictive biomarker for response to the antibody-drug conjugate …
[HTML][HTML] Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung …
Current literature review on the tumor immune micro-environment, its heterogeneity and
future perspectives in treatment of advanced non-small cell lung cancer - PMC Back to Top …
future perspectives in treatment of advanced non-small cell lung cancer - PMC Back to Top …
Potential mechanism of pyrotinib-induced diarrhea was explored by gut microbiome and ileum metabolomics
J Lai, X Zhuo, K Yin, F Jiang, L Liu, X Xu, H Liu… - Anti-Cancer …, 2023 - journals.lww.com
Pyrotinib is a novel epidermal growth factor receptor/human epidermal growth factor
receptor-2 (HER2) tyrosine kinase inhibitor that exhibited clinical efficacy in patients with …
receptor-2 (HER2) tyrosine kinase inhibitor that exhibited clinical efficacy in patients with …
Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
YT Lin, CC Ho, WH Hsu, WY Liao, CY Yang… - Cancer …, 2024 - Wiley Online Library
Abstract Introduction According to current International Association for the Study of Lung
Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to …
Cancer guideline, physicians may first use plasma cell‐free DNA (cfDNA) methods to …